Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.38
OREX's Cash to Debt is ranked lower than
75% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. OREX: 0.38 )
Ranked among companies with meaningful Cash to Debt only.
OREX' s Cash to Debt Range Over the Past 10 Years
Min: 0.38  Med: 12.53 Max: No Debt
Current: 0.38
Equity to Asset 0.21
OREX's Equity to Asset is ranked lower than
93% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. OREX: 0.21 )
Ranked among companies with meaningful Equity to Asset only.
OREX' s Equity to Asset Range Over the Past 10 Years
Min: -3.15  Med: 0.36 Max: 0.86
Current: 0.21
-3.15
0.86
F-Score: 1
Z-Score: -1.62
M-Score: 11.79
WACC vs ROIC
14.40%
-68.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -108.81
OREX's Operating margin (%) is ranked lower than
88% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. OREX: -108.81 )
Ranked among companies with meaningful Operating margin (%) only.
OREX' s Operating margin (%) Range Over the Past 10 Years
Min: -107754.55  Med: -3403.74 Max: -54.99
Current: -108.81
-107754.55
-54.99
Net-margin (%) -71.59
OREX's Net-margin (%) is ranked lower than
86% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. OREX: -71.59 )
Ranked among companies with meaningful Net-margin (%) only.
OREX' s Net-margin (%) Range Over the Past 10 Years
Min: -105954.55  Med: -3422.74 Max: -67.59
Current: -71.59
-105954.55
-67.59
ROE (%) -57.58
OREX's ROE (%) is ranked lower than
89% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. OREX: -57.58 )
Ranked among companies with meaningful ROE (%) only.
OREX' s ROE (%) Range Over the Past 10 Years
Min: -246.53  Med: -116.89 Max: -42.04
Current: -57.58
-246.53
-42.04
ROA (%) -5.65
OREX's ROA (%) is ranked lower than
74% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. OREX: -5.65 )
Ranked among companies with meaningful ROA (%) only.
OREX' s ROA (%) Range Over the Past 10 Years
Min: -101.77  Med: -58 Max: -5.65
Current: -5.65
-101.77
-5.65
ROC (Joel Greenblatt) (%) -10.93
OREX's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. OREX: -10.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OREX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -34518.01  Med: -5974.94 Max: -10.93
Current: -10.93
-34518.01
-10.93
Revenue Growth (3Y)(%) 56.70
OREX's Revenue Growth (3Y)(%) is ranked higher than
96% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. OREX: 56.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OREX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 56.7 Max: 227.2
Current: 56.7
0
227.2
EBITDA Growth (3Y)(%) -29.00
OREX's EBITDA Growth (3Y)(%) is ranked lower than
91% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. OREX: -29.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OREX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -49.8  Med: -24.4 Max: -8
Current: -29
-49.8
-8
EPS Growth (3Y)(%) -25.70
OREX's EPS Growth (3Y)(%) is ranked lower than
85% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. OREX: -25.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OREX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.4  Med: -23.3 Max: -8.7
Current: -25.7
-55.4
-8.7
GuruFocus has detected 6 Warning Signs with Orexigen Therapeutics Inc $OREX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OREX's 10-Y Financials

Financials (Next Earnings Date: 2017-02-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OREX Guru Trades in Q1 2016

Seth Klarman 22,268,399 sh (+881.68%)
Jim Simons 2,381,100 sh (+34.81%)
Paul Tudor Jones 76,473 sh (-24.61%)
» More
Q2 2016

OREX Guru Trades in Q2 2016

Seth Klarman 22,268,399 sh (unchged)
Jim Simons 549,500 sh (-76.92%)
Paul Tudor Jones 12,073 sh (-84.21%)
» More
Q3 2016

OREX Guru Trades in Q3 2016

Seth Klarman 2,226,839 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q4 2016

OREX Guru Trades in Q4 2016

Seth Klarman 2,226,839 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with OREX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:MEIP, NAS:STDY, NAS:EPIX, NAS:PSDV, OTCPK:MGWFF, NAS:LPCN, NAS:AGRX, OTCPK:NRIFF, OTCPK:MRPHF, NAS:ADMP, NAS:JNP, NAS:TYHT, NAS:GALT, NAS:IMMY, NAS:SPHS, OTCPK:ACNNF, OTCPK:ZOMHF, NAS:EVOK, NAS:SCYX, OTCPK:ITHUF » details
Traded in other countries:JXS1.Germany,
Orexigen Therapeutics Inc is a biopharmaceutical company. The Company is engaged in development of pharmaceutical product candidates for the treatment of obesity. Its product candidate includes NB32 and Empatic.

Orexigen Therapeutics Inc was incorporated in Delaware in September 2002. Company is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates are NB32, which has completed Phase III clinical trials and which is currently being studied in a cardiovascular outcomes trial, and Empatic, which has completed Phase II clinical trials. Both NB32 and Empatic regulate appetite and energy expenditure through central nervous system activity. NB32 is a fixed dose combination of bupropion and naltrexone. Company develops its product candidates for large markets traditionally served by primary care physicians. In order to effectively promote NB32 to these physicians, in September 2010, it entered into a collaboration agreement with Takeda to develop and commercialize NB32 in the United States, Canada and Mexico. It maintains an aggressive intellectual property plan, which includes patent and trademark filings in multiple jurisdictions including the United States and other commercially placed markets. It relies on a combination of in-licensed patent rights, its own patent rights, trademarks, trade secrets and know-how to protect NB32 and Empatic. Its products used in clinical trials have been produced by outside contractors under its supervision. Company competes with AstraZeneca, Athersys, Inc., Bristol-Myers Squibb, Norgine BV, Novo Nordisk A/S, among others.

Ratios

vs
industry
vs
history
P/B 0.86
OREX's P/B is ranked higher than
92% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. OREX: 0.86 )
Ranked among companies with meaningful P/B only.
OREX' s P/B Range Over the Past 10 Years
Min: 0.35  Med: 5.5 Max: 1446.67
Current: 0.86
0.35
1446.67
P/S 2.93
OREX's P/S is ranked higher than
51% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. OREX: 2.93 )
Ranked among companies with meaningful P/S only.
OREX' s P/S Range Over the Past 10 Years
Min: 1.2  Med: 138.78 Max: 3995.83
Current: 2.93
1.2
3995.83
Current Ratio 4.17
OREX's Current Ratio is ranked higher than
72% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. OREX: 4.17 )
Ranked among companies with meaningful Current Ratio only.
OREX' s Current Ratio Range Over the Past 10 Years
Min: 1.99  Med: 6.62 Max: 19.3
Current: 4.17
1.99
19.3
Quick Ratio 3.81
OREX's Quick Ratio is ranked higher than
74% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. OREX: 3.81 )
Ranked among companies with meaningful Quick Ratio only.
OREX' s Quick Ratio Range Over the Past 10 Years
Min: 1.99  Med: 6.62 Max: 19.3
Current: 3.81
1.99
19.3
Days Inventory 1.00
OREX's Days Inventory is ranked higher than
99% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. OREX: 1.00 )
Ranked among companies with meaningful Days Inventory only.
OREX' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1
Current: 1
0
1
Days Sales Outstanding 30.93
OREX's Days Sales Outstanding is ranked higher than
86% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. OREX: 30.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
OREX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.2  Med: 16.9 Max: 101.89
Current: 30.93
8.2
101.89
Days Payable 1.00
OREX's Days Payable is ranked lower than
98% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. OREX: 1.00 )
Ranked among companies with meaningful Days Payable only.
OREX' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1
Current: 1
0
1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.90
OREX's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. OREX: -19.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OREX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -178.3  Med: -26.3 Max: -19.9
Current: -19.9
-178.3
-19.9

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.02
OREX's Price/Median PS Value is ranked higher than
99% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. OREX: 0.02 )
Ranked among companies with meaningful Price/Median PS Value only.
OREX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.02  Med: 1.05 Max: 29.49
Current: 0.02
0.02
29.49
Earnings Yield (Greenblatt) (%) -4.55
OREX's Earnings Yield (Greenblatt) (%) is ranked lower than
78% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. OREX: -4.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OREX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.57  Med: 77.1 Max: 2085.3
Current: -4.55
-4.57
2085.3

More Statistics

Revenue (TTM) (Mil) $24.76
EPS (TTM) $ -3.28
Beta2.61
Short Percentage of Float28.16%
52-Week Range $1.65 - 18.40
Shares Outstanding (Mil)14.59

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 33 87
EPS ($) -9.70 -6.72
EPS w/o NRI ($) -9.70 -6.72
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:OREX

Headlines

Articles On GuruFocus.com
Seth Klarman’s Largest New Buys and Adds Feb 15 2016 
Value Investing in BioPharma Nov 18 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
Orexigen Therapeutics' Bright Future Mar 03 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 

More From Other Websites
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results... Feb 17 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 09 2017
Orexigen Therapeutics to Speak at Upcoming Investor Conferences Feb 07 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 06 2017
Orexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl... Jan 25 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 12 2017
Orexigen Therapeutics (OREX) Shares March Higher, Can It Continue? Jan 10 2017
Celgene Issues Preliminary 2016 Results, Lifts 2017 View Jan 10 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 09 2017
Orexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl... Jan 06 2017
Orexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl... Jan 06 2017
Orexigen Therapeutics Highlights Key Business Priorities for 2017 Jan 05 2017
Orexigen Therapeutics Highlights Key Business Priorities for 2017 Jan 05 2017
Wednesday’s Top 5 Biopharma Movers Jan 04 2017
Orexigen Therapeutics Launches "Brains Behind Weight Loss," a Dynamic Patient Focused Campaign to... Jan 03 2017
Orexigen Therapeutics Launches "Brains Behind Weight Loss," a Dynamic Patient Focused Campaign to... Jan 03 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events Dec 30 2016
15 Stocks With The Highest Forecast Sales Growth Dec 23 2016
ETFs with exposure to Orexigen Therapeutics, Inc. : December 21, 2016 Dec 21 2016
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Dec 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)